Aribio announced on October 1 that its solution Teloact, which incorporates new technology to alleviate hair loss symptoms, has received approval from the Ministry of Food and Drug Safety (MFDS) as a functional cosmetic for hair loss.
Aribio, in collaboration with the research team led by former Dankook University professor Shin Deukyong, succeeded in developing a patented ingredient that induces activation of hair follicle stem cells through industry-academic research. The research team demonstrated its efficacy and safety after five years of research and clinical trials. Six domestic patents have already been registered, and by the end of this year, the company plans to file international patents in 12 countries, including the United States, Europe, China, and Japan.
Teloact is based on research into the enzyme 'telomerase,' which is involved in cellular aging and lifespan extension. Telomerase restores telomeres, which shorten during cell division, thereby maintaining cellular vitality and regenerative capacity. When telomerase is activated, dormant hair follicles transition to the growth phase, promoting the generation of new hair.
The Aribio research team independently developed an ultrafine particle technology for the patented ingredient to maximize the mechanism of telomerase action. The patented ingredient is designed to be smaller than the gaps between cells, effectively delivering active components to the scalp. This enables not only the alleviation of hair loss but also simultaneous improvement of scalp health and hair quality.
The clinical trial for Teloact was conducted as a 24-week human application study involving 43 participants. Compared to the control group, hair density increased significantly, and the product was found to be non-irritating in skin irritation tests. During the clinical process, improvements were observed without side effects, including increased scalp blood flow, enhanced scalp elasticity, and the potential to alleviate keratin and oxidative stress. These improvements began to appear at approximately the 4-week or 7-week mark.
Seo Boseung, head of Aribio Biomedical Research Institute, stated, "With MFDS approval for Teloact, we have secured a key growth driver to accelerate revenue expansion in both domestic and overseas markets," adding, "After launching functional cosmetics in the global market, we will also begin research and development of specialized pharmaceuticals for hair loss."
Aribio is currently pursuing a merger with Kosdaq-listed company Solux. The scheduled merger date is January 20, 2026.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
